Skip to main content

Table 1 Patients from whom virus isolates and/or infectious molecular clones were generated

From: Relative resistance of HIV-1 founder viruses to control by interferon-alpha

Patient ID Transmission risk group1 Clade2 Setpoint VL (copies/ml)3 Virus isolation time-points (DFOSx)4 IMCs generated6
CH040 MSM B 13,224 None Founder7
CH058 MSM B 260 285 Founder, 6-month7
CH077 MSM B 3,631 215, 5925 Founder, 6-month7
CH162 HSX C 114,815 None Founder8
CH164 HSX C 575,440 None Founder8
CH185 HSX C 40,738 None Founder8
CH236 HSX C 134,896 None Founder, 6-month9
CH264 HSX C 74,131 None Founder9
CH470 MSM B 23,442 335 Founder, 6-month10
CH850 HSX C 15,488 None Founder, 6-month9
MM23 MSM B 82,958 14, 204, 631, 1535 None
MM24 MSM B 128,021 16, 1322 None
MM25 MSM B 72,600 10 None
MM26 MSM B 34,493 69 None
MM27 MSM B 48,360 28, 1516 None
MM28 MSM B 12,322 6, 1995 None
MM33 MSM B 73,958 12, 1912 None
MM34 MSM B 8,522 25, 2227 None
MM38 MSM B ND 29 None
MM39 MSM B 8,546 11, 1206 None
SUMA MSM B 17,245 None Founder7
  1. 1Transmission risk group: MSM = men who have sex with men; HSX = heterosexual.
  2. 2Clade of infecting virus: all clade B virus infected patients were recruited from clinical sites in the UK or USA, whilst clade C virus infected patients were recruited from clinical sites in Africa.
  3. 3Setpoint persisting viral load established, calculated as described by Fellay et al.[65].
  4. 4Time-points during infection when plasma from which virus isolates were subsequently derived was cryopreserved, expressed as days following onset of symptoms of the acute retroviral syndrome (DFOSx); or 5for those patients where the time of onset of symptoms was not known, expressed as days post Fiebig stage I/II of acute infection [66].
  5. 6HIV-1 IMCs generated: founder = IMC corresponding to the deduced sequence of the founder virus that established systemic infection; 6-month = IMC corresponding to the 6-month consensus virus sequence.
  6. 7SGA and viral sequence analysis reported in [67]; construction of the founder IMC described in [68]; construction of the 6-month IMC described in [69].
  7. 8SGA, viral sequence analysis and construction of the founder IMC described in [70].
  8. 9SGA and viral sequence analysis, unpublished data of G.M. Shaw and B.H. Hahn; founder and 6-month IMC construction, unpublished data of C. Ochsenbauer and J.C. Kappes.
  9. 10SGA, viral sequence analysis and construction of the founder IMC described in [70]; 6-month IMC construction, unpublished data of C. Ochsenbauer and J.C. Kappes.